TTechnology Read More iPhone Price Hike, Siri AI Upgrades, Buffett Criticism And More: This Week In Appleverse – Apple (NASDAQ:AAPL)September 8, 2025 The week was packed with news, and we’ve got it all covered. Here’s a quick roundup of the…
EEconomy Read More Veteran Economist Warns About Converging Crises, ‘Worse Than 2008’ – Vanguard Total Stock Market ETF (ARCA:VTI), SPDR S&P 500 (ARCA:SPY)September 3, 2025 Economist Fred Harrison, known for accurately forecasting the 2008 financial crisis and previous downturns using his 18-year property…
EEconomy Read More Truflation’s Inflation Spike Rockets To 7-Month Peak, Casting Doubt On Fed Rate-Cut Cheerleaders, Says Jim Bianco – Invesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY)September 3, 2025 The President and founder of Bianco Research LLC., Jim Bianco, is sounding the alarm on inflation, pointing to…
HHealthcare Read More What’s Going On With Novo Nordisk Stock Monday? – Novo Nordisk (NYSE:NVO)August 25, 2025 The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate…
PPersonal finance Read More Warren Buffett’s Tip for the Middle Class: ‘Do Not Save What Is Left After Spending, but Spend What Is Left After Saving’August 25, 2025 Warren Buffett once shared his top financial tips for the middle class. What Happened: Buffett has always been…
VVirtual reality Read More Apple’s Vision Pro Struggles To Gain Traction Amid Slow Release Of Immersive Video – Apple (NASDAQ:AAPL)August 19, 2025 Apple Inc. AAPL is reportedly grappling with the slow uptake of its Vision Pro headset, attributed to its high…
BBusiness Read More Why Is UnitedHealth Stock Trading Higher Friday? – UnitedHealth Group (NYSE:UNH)August 15, 2025 UnitedHealth Group Inc. UNH shares climbed Friday after high-profile investors Michael Burry and Warren Buffett took positions in…
HHealthcare Read More Eli Lilly’s Orforglipron Data Is Not Disastrous: Analyst – Eli Lilly (NYSE:LLY)August 12, 2025 Eli Lilly and Co LLY released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational…